Impax Laboratories, Inc. (NASDAQ:IPXL) – Research analysts at Cantor Fitzgerald increased their FY2017 earnings per share estimates for shares of Impax Laboratories in a research report issued to clients and investors on Sunday. Cantor Fitzgerald analyst L. Chen now expects that the specialty pharmaceutical company will post earnings of $0.60 per share for the year, up from their previous forecast of $0.57. Cantor Fitzgerald has a “Overweight” rating and a $35.00 price target on the stock. Cantor Fitzgerald also issued estimates for Impax Laboratories’ FY2018 earnings at $0.71 EPS.
IPXL has been the subject of several other reports. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the stock a “hold” rating in a research report on Wednesday, August 9th. UBS AG upped their price objective on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a research report on Monday, October 30th. Citigroup Inc. increased their price target on Impax Laboratories to $23.00 and gave the company a “buy” rating in a research report on Tuesday, September 19th. Zacks Investment Research cut Impax Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Piper Jaffray Companies set a $17.00 price target on Impax Laboratories and gave the company a “hold” rating in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. Impax Laboratories has a consensus rating of “Hold” and a consensus target price of $19.60.
Impax Laboratories (IPXL) opened at $17.17 on Tuesday. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $1,356.28, a PE ratio of 26.91, a PEG ratio of 1.13 and a beta of 0.99. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $25.70.
Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The company had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. Impax Laboratories’s revenue for the quarter was down 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.37 earnings per share.
Several institutional investors and hedge funds have recently added to or reduced their stakes in IPXL. Public Employees Retirement System of Ohio lifted its position in shares of Impax Laboratories by 12.7% in the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock valued at $111,000 after buying an additional 780 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Impax Laboratories in the third quarter valued at approximately $201,000. Stevens Capital Management LP acquired a new stake in shares of Impax Laboratories in the third quarter valued at approximately $203,000. Quantbot Technologies LP lifted its position in shares of Impax Laboratories by 279.0% in the third quarter. Quantbot Technologies LP now owns 10,031 shares of the specialty pharmaceutical company’s stock valued at $203,000 after buying an additional 7,384 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new stake in shares of Impax Laboratories in the second quarter valued at approximately $207,000. 88.32% of the stock is owned by institutional investors.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.